Containment
Cytotoxic & ADC Handling CDMOs
Compare CDMOs with cytotoxic compound handling and ADC manufacturing capabilities. Filter by containment level, bioconjugation expertise, and regulatory approvals.
737 companies listed
About Cytotoxic & ADC Handling
Cytotoxic compound handling covers the manufacturing of drugs designed to kill cells -- primarily cancer chemotherapy agents and ADC payloads. These compounds are inherently hazardous to manufacturing workers and require specialized containment, waste handling, and decontamination procedures that go beyond standard pharmaceutical manufacturing.
ADC manufacturing adds unique requirements: the cytotoxic payload must be synthesized under high containment, then conjugated to a monoclonal antibody under aseptic conditions. This intersection of high-potency chemistry and sterile biologics processing is one of the most demanding manufacturing challenges in pharma. CDMOs with both capabilities under one roof command premium positioning.
Companies (737)
ABFEN FARMA
Turkey
ABFEN FARMA is a pharmaceutical CDMO offering comprehensive services.
Biologics Drug SubstanceBiologics Drug ProductBiologics Manufacturing
Altruist Biologics
China
Altruist Biologics is a pharmaceutical CDMO offering comprehensive services.
Sterile InjectableSterile Fill/FinishFill/Finish (Vials)
Frequently Asked Questions
What special safety measures do cytotoxic CDMOs implement?+
Key measures include: engineering controls (isolators, negative pressure, HEPA filtration), administrative controls (restricted access, dedicated personnel, training programs), PPE (powered air-purifying respirators, chemotherapy-rated gloves, disposable gowns), medical surveillance (baseline and periodic health monitoring for exposed workers), spill containment and decontamination procedures, and cytotoxic waste disposal per EPA regulations.
Can the same CDMO handle both the antibody and cytotoxic payload for ADCs?+
Few CDMOs can handle all three ADC components (antibody, payload, conjugation) in-house. Most ADC supply chains use separate CDMOs for antibody production (biologics facility) and payload synthesis (high-potency chemistry facility), with a third CDMO (or one of the first two) handling bioconjugation. Some CDMOs have invested in integrated ADC capabilities, combining biologics and contained chemistry under one roof. This integration reduces tech transfer complexity and supply chain risk.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
